Biogen Idec   2Q Revenues: $2.4 billion (+40%) 2Q Earnings: $723.1 million (+47%) YTD Revenues: $4.6 billion (+45%) YTD Earnings: $1.2 billion (+31%) Comments: Growth in the quarter was driven by continued uptake of MS drug TECFIDERA, with revenues of $700 million, consisting of $585 million in U.S. sales and $115 million in sales outside the U.S. TYSABRI revenues were $533 million, up 38%. Avonex revenues were flat at $774 million in the quarter. Net revenues relating to RITUXAN and GAZYVA ...